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Martínez-Moreno JM, Muñoz-Castañeda JR, Herencia C,
Montes de Oca A, Estepa JC, Canalejo R, Rodríguez-Ortiz ME,
Perez-Martinez P, Aguilera-Tejero E, Canalejo A, Rodríguez M,
Almadén Y. In vascular smooth muscle cells paricalcitol prevents
phosphate-induced Wnt/-catenin activation. Am J Physiol Renal
Physiol 303: F1136–F1144, 2012. First published August 8, 2012;
doi:10.1152/ajprenal.00684.2011.—The present study investigates the
differential effect of two vitamin D receptor agonists, calcitriol and
paricalcitol, on human aortic smooth muscle cells calcification in
vitro. Human vascular smooth muscle cells were incubated in a high
phosphate (HP) medium alone or supplemented with either calcitriol
108M (HP  CTR) or paricalcitol 3·108 M (HP  PC). HP
medium induced calcification, which was associated with the upregu-
lation of mRNA expression of osteogenic factors such as bone
morphogenetic protein 2 (BMP2), Runx2/Cbfa1, Msx2, and osteocal-
cin. In these cells, activation of Wnt/-catenin signaling was evi-
denced by the translocation of -catenin into the nucleus and the
increase in the expression of direct target genes as cyclin D1, axin 2,
and VCAN/versican. Addition of calcitriol to HP medium (HP 
CTR) further increased calcification and also enhanced the expression
of osteogenic factors together with a significant elevation of nuclear
-catenin levels and the expression of cyclin D1, axin 2, and VCAN.
By contrast, the addition of paricalcitol (HP  PC) not only reduced
calcification but also downregulated the expression of BMP2 and
other osteoblastic phenotype markers as well as the levels of nuclear
-catenin and the expression of its target genes. The role of Wnt/-
catenin on phosphate- and calcitriol-induced calcification was further
demonstrated by the inhibition of calcification after addition of Dick-
kopf-related protein 1 (DKK-1), a specific natural antagonist of the
Wnt/-catenin signaling pathway. In conclusion, the differential ef-
fect of calcitriol and paricalcitol on vascular calcification appears to
be mediated by a distinct regulation of the BMP and Wnt/-catenin
signaling pathways.
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UREMIC PATIENTS FREQUENTLY present vascular calcifications
(VC), which contributes to the high rate of cardiovascular
morbidity and mortality observed in these patients (61). The
generation of VC in uremic patients is multifactorial, and the
mechanisms are partially understood (35). Abnormal mineral
metabolism, and particularly the accumulation of phosphate,
plays a central role in the generation of VC (3, 25). Chronic
inflammation has also been proposed as an important factor in
the process of VC (34, 50).
Calcitriol [1,25(OH)2D3], the most active metabolite of
vitamin D, is a key regulator of mineral metabolism through its
direct effect on intestine, kidney, bone, and parathyroid glands.
Chronic kidney disease (CKD) patients, often develop second-
ary hyperparathyroidism (2°HPT) because of the retention of
phosphate and the deficiency of calcitriol synthesis, both due to
the reduction of functional renal mass, which eventually lead to
hypocalcemia. Thus, in the last decades, therapeutic strategies
to control 2°HPT incorporated high doses of vitamin D, mainly
as calcitriol, that may contribute to the development of VCs
(13). The vitamin D analog 19-nor-1,25(OH)2D2 (paricalcitol)
is now commonly used to treat 2°HPT in CKD patients
because it effectively suppress parathyroid hormone but is less
calcemic and phosphatemic than calcitriol (29, 53).
The administration of calcitriol to CKD patients may cause
VC by increasing the serum levels of calcium and phosphate.
Other studies (45) have suggested that calcitriol and other
vitamin D receptor (VDR) activators such as paricalcitol may
have a direct effect on VC that is independent of calcium and
phosphorus. Paricalcitol seems to produce less calcification
than calcitriol (4, 28, 33). However, the cellular mechanisms
driving the differential effects of calcitriol and paricalcitol on
VC have not been elucidated. We hypothesized that factors
regulating osteogenic differentiation of vascular smooth mus-
cle cells (VSMCs) may respond differently to calcitriol and
paricalcitol.
Bone morphogenetic proteins (BMPs) and proteins of the
Wnt family are extremely potent anabolic regulators of bone
formation, and both have been implicated in the regulation of
VC (7, 17, 31, 49, 51, 57). BMP2 upregulates transcription
factors as the runt-related transcript factor 2 (Runx2/Cbfa1)
and the Msh homeobox 2 (Msx2), master regulators of osteo-
genesis (30). Furthermore, Wnt signaling, which is essential
for the commitment of pluripotent mesenchymal cells, has also
been shown to be activated during the development of VC in
vivo and in vitro (5, 8, 23, 31, 51). Wnt proteins (revised in 26)
are a large family of secreted signaling molecules that signal
through binding to a coreceptor complex formed by the pro-
teins of the frizzled (Fzd) family and the lipoprotein receptor-
related 5/6 proteins (Lrp5/6). The activation of the canonical
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Wnt pathway results in the inactivation of a destruction com-
plex that phosphorylates -catenin and targets it for ubiquitin-
proteasome-mediated degradation; thus -catenin is able to
translocate to the nucleus and regulates the expression of target
genes.
The aim of the present study was to investigate possible
differences between the effect of calcitriol and paricalcitol on
osteogenic signals, mainly the Wnt/-catenin signaling, in
human aortic smooth muscle cells (HASMCs) in vitro.
MATERIALS AND METHODS
Cell culture. HASMCs were obtained from Clonetics (Lonza,
Walkersville, MD). Cells were cultured in DMEM supplemented with
15% heat-inactivated FBS (BioWhittaker), Na piruvate (1 mmol/l),
glutamine (4.5 g/l), penicillin (100 U/ml), streptomycin (100 mg/ml),
and HEPES (20 mmol/l) at 37°C in a humidified atmosphere with 5%
CO2. HASMCs of passage 5–8 were used in the experiments. To
induce calcification, after reaching 80% confluence, HASMCs were
incubated for 9 days in a high phosphate medium (calcification
medium) that contained Na2HPO4
3 and NaH2PO4
3 salts in 1:2
proportion (Sigma Aldrich) to obtain a final phosphate concentration
of 3.3 mmol/l. The medium was replaced with fresh medium every
2–3 days. Depending on the experiments, calcification medium was
supplemented with calcitriol 108M, paricalcitol 3·108M, or other
drugs such as Dickkopf-related protein 1 (DKK-1; ref 5439-DK-010;
R&D Systems; 100 ng/ml; a secreted, endogenous extracellular Wnt/
-catenin inhibitory gene product that is commercially available).
Cells that were incubated in normal phosphate (0.9 mmol/l) medium
were used as controls.
Assessment of calcium deposition. After 9 days of incubation,
calcification was quantified. Cells were decalcified with HCl (0.6
mol/l) for 24 h. The calcium content of the supernatants was deter-
mined by spectrophotometer at 612 nm by a kit containing phenol-
sulphonephthalein dye (no. DICA008, QuantiChrom calcium assay
kit; BioAssay Systems). Then, the cells were washed three times with
PBS (Sigma Aldrich) and solubilized in 0.1 mol/l NaOH/0.1% SDS.
The protein content was measured using the Bio-Rad protein assay
(Bio-Rad Laboratories, Munich, Germany), and the calcium content
was normalized for total protein.
Real-time RT-PCR. Total RNA was isolated from each sample of
HASMCs using 500 l Trizol (Sigma) by processing according to the
manufacturer’s recommendation. Real-time RT-PCR was performed
in duplicate with QuantiTect SYBR Green one-step RT-PCR Kit (ref.
no. 204243; Qiagen) in a final volume of 20 ul from 30 ng of total
RNA. All PCR amplifications were carried out using Lightcycler 480
(Roche Molecular Biochemicals, Indianapolis, IN). The expression of
target genes was normalized to the expression of GAPDH. The
primers for PCR amplification are indicated in Table 1.
Protein extracts and Western blot. Proteins were isolated from
HASMCs using lysis buffer containing HEPES (10 mmol/l), KCl (10
mmol/), EDTA (0.1 mmol/l), EGTA (0.1 mmol/l), dithiothreitol (1
mmol/l), PMSF (0.5 mmol/l), protease inhibitor cocktail (70 mg/ml;
Sigma Aldrich), and Igepal CA-630 (0.6%) at pH 7.9. The suspension
was centrifuged, and the supernatant (cytosolic extract) was stored.
Nuclear extracts were obtained by incubating the pellet separated
from the cytosolic extract in a lysis buffer containing HEPES (20
mmol/l), NaCl (0.4 mmol/l), EDTA (1 mmol/l), EGTA (1 mmol/l),
dithiothreitol (1 mmol/l), PMSF (1 mmol/l), and protease inhibitor
cocktail (46 mg/ml) at pH 7.9. Protein concentration was determined
with the Bradford method (Bio-Rad Laboratories, Munich, Germany).
For Western blot, equal amounts of protein were electrophoresed in
10% SDS-polyacrylamide gel (Invitrogen, Carlsbad, CA) and subse-
quently transferred to a nitrocellulose membrane (Invitrogen). The
membranes were blocked with 5% nonfat dried milk for 1 h at room
temperature and then incubated with primary antibody for 2 h at room
temperature. Primary antibodies used included rabbit polyclonal
-catenin antibody (ref. no. L9562; Cell Signaling) and rabbit poly-
clonal TFIIB antibody (ref. no. SC-225; Santa Cruz Biotechnology,
Santa Cruz, CA). Blots were immunolabeled using a horseradish
peroxidase-conjugated secondary antibody and developed on autora-
diographic film using the ECL Plus Western blotting detection system
(Amersham Biosciences, Little Chalfont, England). Specific bands
were quantified by densitometric analyses with Quantity One 4.4.0
software (Bio-Rad Laboratories) and were normalized to TFIIB levels.
Confocal microscopy. Cells were seeded on coverslips, and after
reaching 90% confluence, they received the different treatments for 24
h. Then, they were rinsed in PBS and fixed and permeated in cold 50%
methanol for 2 min, cold 100% methanol for 20 min, and cold 50%
methanol for 2 min. The specimens were subsequently washed once in
PBS (3  5 min) and incubated for 2 h with anti--catenin antibody
(1:50; BD Pharmigen, Franklin Lakes, NJ) in blocking solution (1%
BSA) at room temperature. After being washed with PBS (3  5 min),
specimens were incubated for 1 h with Alexa Fluor 488 F(ab=)2
fragment of rabbit anti-mouse IgG (1:500; ref. no. A-21204; Invitro-
gen) in PBS containing 1% BSA. After a final wash with PBS (3 
5 min), the specimens were counterstained with DAPI for nuclear
stain. Cells were mounted on slides to examine fluorescence using a
LSM 5 Exciter Carl Zeiss confocal microscope. Pictures were ob-
tained at 40 in Axio Observer Z1 inverted confocal microscope
(LSM5 Exciter Zeiss). ImageJ software (National Institutes of Health)
was used to analyze confocal immunofluorescence staining. Mander’s
coefficient M2 plugin (DAPI vs. green) was used to analyze nuclear
translocation of -catenin. Mander’s coefficient M2 is the percentage
of above-background pixels in blue color (DAPI) that overlap above-
background pixels in green color (-catenin).
Statistical analysis. Results are expressed as means  SE. The
difference between means for three or more groups was assessed by
one-way ANOVA followed by post hoc Duncan analysis. The difference
between means for two different groups was determined by t-test. A P
value 0.05 was considered significant. These analyses were performed
with the assistance of a computer program (SPSS 15.0, Chicago, IL).
RESULTS
Effect of calcitriol and paricalcitol on VSMC calcification.
Incubation of HASMCs in a high phosphate (3.3 mmol/l)
medium for 9 days (HP) induced calcification compared with
Table 1. Primers used for quantitative real-time RT-PCR
Gene Sense Primer Antisense Primer
GAPDH 5=-TGATGACATCAAGAAGGTGGTGAAG-3= 5=-TCCTTGGAGGCCATGTGGGCCAT-3=





BMP2, bone morphogenetic protein 2.
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cells maintained in a medium with 0.9 mmol/l phosphate
(control; P  0.05; Fig. 1). The addition of calcitriol (108 M)
to cells in HP medium (HP  CTR) further increased the
degree of calcification observed with HP alone (P  0.05).
Conversely, the addition of paricalcitol (3  108 M; HP 
PC) produced a significant reduction in calcification relative to
the observed in cells in HP medium (P  0.05). Nevertheless,
in the HP  PC cells the calcium content remained higher than
in control cells cultured in 0.9 mmol/L P (P  0.05).
Osteoblast phenotype. The levels of BMP2 mRNA were
greater in cells incubated in HP medium than in controls (P 
0.05; Fig. 2A). The addition of calcitriol further increased the
expression of BMP2 mRNA compared with the HP cells (P 
0.05). In cells treated with paricalcitol, the levels of BMP2
mRNA were not different from control cells.
The gene expression of the osteoblastic-specific marker
Runx2 was significantly increased in cells on HP compared
with controls (P  0.05; Fig. 2B). Again calcitriol caused
additional increase of Runx2 expression (P  0.05 vs. HP
cells), whereas paricalcitol failed to increase the expression of
Runx2 mRNA beyond the values observed in HP cells.
Similarly to that observed with Runx2, the expression of
Msx2 mRNA was increased in HP and further increased by
addition of calcitriol (Fig. 2C). The addition of paricalcitol
decreased the Msx2 mRNA levels to control values. The
expression of Bglap/osteocalcin (OC) was not increased by HP
but it increased when calcitriol was added to the HP medium
(Fig. 2D). By contrast, paricalcitol did not modify the OC
expression.
Role of the canonical Wnt/-catenin signaling pathway.
Activation of the Wnt/-catenin signaling pathway results in
nuclear translocation of -catenin. The presence of -catenin
in the nucleus was assessed by Western blotting of nuclear
extracts. The incubation of cells in HP induced a significant
increase of the expression of nuclear -catenin compared with
controls (P  0.05). The addition of calcitriol to HP medium
increased the nuclear content of -catenin; however, the addi-
tion of paricalcitol caused a reduction in the levels of nuclear
-catenin to a level similar to that observed in control cells
(Fig. 3A). Intracellular localization of -catenin was visualized
by immunofluorescence using confocal microscopy (Fig. 3B).
Control cells showed immunofluorescence staining of -catenin
only in the cytoplasm, whereas cells cultured in HP showed
marked expression of -catenin at the nuclear level. HP  CTR
cells also exhibited marked staining for nuclear -catenin. By
contrast, in HP  PC, -catenin expression was mainly re-
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Fig. 1. Effect of calcitriol and paricalcitol on human aortic smooth muscle cell
(HASMC) calcification. HASMCs are incubated for 9 days in a high (3.3
mmol/l) phosphate (HP) medium (calcification medium) alone or supple-
mented with either calcitriol 108 M (HP  CTR) or paricalcitol 3·108 M
(HP  PC). Cells incubated in normal phosphate (0.9 mmol/l) medium are
used as controls. Calcium content is determined with the phenolsulphoneph-
thalein dye. Bars are means  SE (5 independent experiments; 6 repetitions in
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Control HP HP+CTR HP+PC
Fig. 2. Effect of calcitriol and paricalcitol on the expression of markers of osteoblastic phenotype during HASMC calcification. HASMCs are incubated for 9
days in a high (3.3 mmol/l) phosphate (HP) medium (calcification medium) alone or supplemented with either calcitriol 108 M (HP  CTR) or paricalcitol
3·108 M (HP  PC). Cells incubated in normal phosphate (0.9 mmol/l) medium are used as controls. mRNA levels are analyzed by real-time RT-PCR technique.
Expression of target genes are normalized to the expression of GAPDH. A: bone morphogenetic protein 2 (BMP2) mRNA expression. B: Runx2/Cbfa1 mRNA
expression. C: Msx2 mRNA expression. D: osteocalcin/Bglap mRNA expression. Bars are means  SE (3 independent experiments; 6 repetitions in each
experiment). OC, osteocalcin. *P  0.05 vs. control. #P  0.05 vs. HP.
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coefficient M2 plugin (DAPI vs. green), confirmed the signif-
icance of differences in the levels of -catenin fluorescence in
HP and HP  CTR compared with control cells (P  0.05 and
P  0.05, respectively; Fig. 3C).
The relevance of Wnt/-catenin signaling activation in cal-
cification was tested by addition to culture medium (100 ng/ml)
of DKK-1, a commercially available specific endogenous ex-
tracellular antagonist of the Wnt signaling (1, 26). As shown in
Fig. 4, the addition of DKK-1 reduced the level of calcification
induced by high phosphate (P  0.05 vs. HP cells) and
prevented the increase in calcification induced by calcitriol
(P  0.05 vs. HP  CTR cells); a trend toward a decreased
calcification, although not significant, was also observed after
addition of DKK-1 to HP  PC cells. The effect of DKK-1 on
-catenin translocation was also evaluated by confocal immu-
nofluorescence (Fig. 3, B and C). The increase of nuclear
-catenin expression in HP and HP  CTR cells was abolished
by coincubation with DKK-1 (P  0.05 vs. controls).
Additional direct Wnt/-catenin transcriptional targets were
examined, including cyclin D1 (an early marker of cells enter-
ing the cell cycle), VCAN/versican (a large chondroitin sulfate
proteoglycan; a member of the aggrecan/versican proteoglycan
family), and axin 2 (axis inhibition protein 2 or conductin; a
member of the Wnt/-catenin signaling pathway that regulates
the stability of -catenin). Effects of cotreatment with the
inhibitor DKK-1 on the expression of genes were also tested
(Fig. 5). The mRNA expression of cyclin D1 was similarly
elevated in cells in HP and HP  CTR compared with control
cells (P  0.05). In cells treated with HP  PC, the cyclin D1
mRNA level was greater than in control (P  0.05) but lower
than in HP and HP  CTR cells (P  0.05). Addition of
DKK-1 dramatically reduced cyclin D1 mRNA to a level not
different from that of control. VCAN expression was also
increased in HP, HP  CTR, and HP  PC cells over control
(P  0.05). Cotreatment with DKK-1 significantly reduced
VCAN mRNA levels to control values in all the groups.
Finally, compared with control, axin 2 mRNA expression was
elevated in HP and HP  CTR (P  0.05) but not in HP  PC
group; this increase was abolished by DKK-1 (P  0.05).
DISCUSSION
In the present study, we have explored the differential effect
of two VDR agonists, calcitriol and paricalcitol, on VSMC










































































Fig. 3. Effect of calcitriol and paricalcitol on the canonical Wnt/-catenin signaling pathway during HASMC calcification. HASMCs are incubated for 24 h in
a high (3.3 mmol/l) phosphate (HP) medium (calcification medium) alone or supplemented with either calcitriol 108 M (HP  CTR) or paricalcitol 3·108 M
(HP  PC). Cells incubated in normal phosphate (0.9 mmol/l) medium are used as controls. A: levels of nuclear -catenin is assessed by western blotting of
nuclear extracts. Image represents 3 different experiments. Quantification is performed by measurement of the integrated optical density (OD) and normalized
to TFIIB levels. Data are means  SE of the 3 independent experiments. *P  0.05 vs. control. #P  0.05 vs. HP. B: HASMCs are incubated for 24 h in a
high (3.3 mmol/l) phosphate (HP) medium (calcification medium) alone or supplemented with either calcitriol 108 M (HP  CTR) or paricalcitol 3·108 M
(HP  PC) alone or with the addition to culture medium (100 ng/ml) of commercially available Dickkopf-related protein 1 (DKK-1), a specific endogenous
extracellular antagonist of the Wnt signaling. Intracellular localization of -catenin is visualized by immunofluorescence using confocal microscopy. For each
treatment, -catenin staining (green immunofluorescence) is shown at left; at middle, the same sample is counterstained with DAPI (blue) for nuclear stain; the
merged image is shown at right. Images represent 3 different experiments. C: quantification of nuclear -catenin staining is performed by the Mander’s coefficient
(M2 plugin: DAPI vs. green). *P  0.05 vs. control. #P  0.05 vs. the same treatment without DKK-1.
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calcification in vitro. We found that calcitriol increased calci-
fication, which appeared to be associated with the activation of
the Wnt/-catenin and BMP2 signaling pathways. By contrast,
paricalcitol decreased calcification, which was accompanied by
an inhibition of the Wnt/-catenin pathway and downregula-
tion of osteoblastic gene expression.
As previously demonstrated by us and other researchers (6,
36, 40, 44, 47, 49, 58), VSMCs cultured in high phosphate
undergo osteogenic transformation and calcification. BMPs
and Wnt ligands have been implicated in the regulation of both
osteoblastic transdifferentiation of aortic VSMCs in vitro and
VC (7, 17, 31, 49, 51, 57). In our study, we found that the
calcification process was associated with the upregulation of
osteogenic factors such as BMP2, the transcription factors
Runx2/Cbfa1 and Msx2, and the procalcificant protein OC.
This is in agreement with previous results (56) showing that the
expression of all these markers was significantly induced in
calcified vessels. BMP2 is a key factor for osteogenic differ-
entiation of mesenchymal cells that upregulates Runx2 and
Msx2 (30). OC is a downstream target gene of Runx2 and
Msx2 (16).
In the present study, we also show that calcification of the
HASMCs is also associated with a concomitant activation of
the canonical Wnt/-catenin signaling pathway. This was
quantitatively demonstrated both immunocytochemically by
the translocation of -catenin into the nucleus and by the
significant increase of the expression of nuclear -catenin by
Western blotting. Furthermore, the addition of DKK-1, a se-
creted, endogenous extracellular Wnt/-catenin inhibitory
gene product (1, 26) that is commercially available, inhibited
the calcification and the concomitant cellular changes induced
by high phosphate.
The activation of -catenin signaling modulates osteoblast
proliferation and differentiation (32, 41). Other authors (22)
observed VSMC proliferation in vessels developing calcifica-
tion. Notably, we demonstrated that the calcification observed
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Fig. 5. Effect of calcitriol and paricalcitol on the expression of -catenin direct
transcriptional target genes, cyclin D1, axin 2, and VCAN/versican, during
HASMC. HASMCs are incubated for 24 h in a high (3.3 mmol/l) phosphate
(HP) medium (calcification medium) alone or supplemented with either cal-
citriol 108 M (HP  CTR) or paricalcitol 3·108 M (HP  PC) alone or with
the addition to culture medium (100 ng/ml) of commercially available DKK-1,
a specific endogenous extracellular antagonist of the Wnt signaling. Cells
incubated in normal phosphate (0.9 mmol/l) medium are used as controls.
mRNA levels are analyzed by real-time RT-PCR technique. Expression of
target gene mRNA is normalized to the expression of GAPDH. Bars are
means  SE (3 independent experiments; 6 repetitions in each experiment).












































Fig. 4. Effect of the inhibition of the canonical Wnt/-catenin signaling
pathway by DKK-1 on HASMC. HASMCs are incubated for 24 h in a high
(3.3 mmol/l) phosphate (HP) medium (calcification medium) alone or supple-
mented with either calcitriol 108 M (HP  CTR) or paricalcitol 3·108 M
(HP  PC) alone or with the addition to culture medium (100 ng/ml) of
commercially available DKK-1, a specific endogenous extracellular antagonist
of the Wnt signaling. Cells incubated in normal phosphate (0.9 mmol/l)
medium are used as controls. Calcium content is determined with the phenol-
sulphonephthalein dye. Bars are means  SE (3 independent experiments; 6
repetitions in each experiment). *P  0.05 vs. control. $P  0.05 vs. HP.
#P  0.05 vs. the same treatment without DKK-1.
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significant increase in the expression of cylin D1, an early
marker of cell proliferation. Cyclin D1 has been shown to be a
direct target gene of the activation of the canonical Wnt/-
catenin (52), and it is required for propagation of specific types
of osteoprogenitors at various developmental stages (32). Im-
portantly, it has also been shown to be upregulated in VSMCs
in response to Wnt signaling (59). Thus the increase of the
cyclin D1 mRNA levels that we have observed is in accordance
with previous data (5, 41) reporting that in the vasculature nuclear
-catenin signals may drive VSMC proliferation. The upregula-
tion of this and other direct transcriptional target genes as axin
2 (62) and VCAN (42), as well as the abrogation of this effect
by DKK-1 that we have observed in this study, is consistent
with the activating effect of the Wnt/-catenin signaling on VC
of HASMCs.
The role of BMP and Wnt signaling on VC remains to be
elucidated (31). Both contribute to the regulation of bone mass
by promoting osteogenesis through the direct stimulation of
Runx2 gene expression (12). However, the molecular interac-
tions between these pathways in osteoblast differentiation and
bone formation are not totally defined (20). Most studies have
suggested that BMP acts upstream of Wnt signaling (20). The
study by Rawadi et al. (43) showed that the capacity of BMP2
and Shh (Sonic hedgehog homolog gene) to induce alkaline
phosphatase relies on Wnt expression and the effects of BMP2
on extracellular matrix mineralization by osteoblasts are me-
diated by the induction of a canonical Wnt/ catenin autocrine
loop. In a recent study, Rodriguez-Carballo et al. (46) investi-
gated the cooperative effects of BMP and the Wnt canonical
pathway on the expression of the early osteogenic master genes
Dlx5, Msx2, and Runx2 in osteoblast differentiation. They
found that induction of these genes is mediated by the forma-
tion of both protein-protein interactions between them and
cooperative transcriptional complexes of BMP-dependent-ac-
tivated Smads and TCF4/-catenin that bind to DNA-binding
sites. BMPs and Wnt ligands have also been implicated in the
regulation of osteoblastic transdifferentiation of VSMCs (31).
The studies of Towler and colleagues (5, 34, 51) with different
in vivo and in vitro models described the involvement of a
BMP-Wnt/-catenin axis in the osteogenic regulation of VC.
Nonetheless, canonical Wnt/-catenin signaling acting up-
stream of BMP signaling has been also reported. This is the
case for the regulation of dorsoventral polarity in the limb (54)
or the inhibition of oligodendrocyte maturation (9) during
development. We are aware of one single study (55) on this
Wnt-BMP hierarchy in osteoblast differentiation, which shows
that osthole, a coumarin-like derivative extracted from Chinese
herbs, stimulated osteoblast differentiation through a Wnt/-
catenin dependent induction of BMP2 expression.
On the other hand, the relative contribution of canonical and
noncanonical Wnts in the regulation of VC has to be explored
further (51). Indeed, the role of Wnt signaling in osteogenic
differentiation during bone development is still controversial.
Canonical Wnt signaling may suppress osteogenic differentia-
tion or activate osteogenesis under certain cellular conditions.
Lack of uniformity in the literature may have resulted from
differences in baseline cellular conditions, species employed,
or even in the experimental conditions and stimuli applied (26).
The effect of noncanonical Wnt activation through Wnt5a in
osteogenesis has been demonstrated in adult stem cells (48)
and MC3T3E1 (preosteoblasts) cells (11). The specific Wnt
milieu regulating VC is unknown; 19 murine Wnt genes exist
and both canonical agonists (Wnt3a, Wnt7) and noncanonical
ligands (Wnt5) that inhibit canonical Wnt actions were upregu-
lated in an Msx2-dependent cardiovascular calcification model
in vivo (51). Whether phosphate could be a new stimulator of
noncanonical Wnt pathways is presently unknown.
Many in vivo studies (2, 4, 14, 15, 27, 33) have reported that
the treatment of uremic animals with vitamin D produces an
increase in VC. Koleganova et al. (22) showed that a moderate
dose of calcitriol produced VC in both sham and uremic rats.
This effect was observed despite no changes in serum levels of
calcium and phosphate, suggesting that calcitriol may directly
affect VC. Interestingly, in a model of uremic rats, the induc-
tion of aortic calcifications by calcitriol was partially reversible
after discontinuation of calcitriol administration (2). In vitro
studies were performed to evaluate a direct effect of calcitriol
on VSMCs calcification. Jono et al. (19) showed that in
VSMCs cultured with high phosphate, the addition of an
increasing concentration of calcitriol produced a dose-depen-
dent increase in calcification. Recently, Zebger and Gong (63)
observed that a high-dose calcitriol treatment induced transfor-
mation of VSMCs into osteoblastic phenotype both in uremic
rats and in vitro; this was associated with upregulation of
proteins regulating mineralization and the osteogenic transcrip-
tion factor Osterix.
In the present study, we assessed the effect of calcitriol and
paricalcitol at concentrations usually tested in in vitro studies
with VSMCs (4, 18, 49), which are in accordance with their
therapeutic dosages in vivo. The results show that cells ex-
posed to calcitriol exhibited a significant increase in calcifica-
tion; by contrast, the addition of paricalcitol to the medium
resulted in a significant decrease of calcification. Previous
experimental studies (4, 28, 33) have shown that paricalcitol
produced less calcification than calcitriol. Thus here we con-
firm that paricalcitol also exerts beneficial effects on the
development of VCs. Importantly, paricalcitol tended to sup-
press the calcification induced by phosphate; this is in marked
contrast with calcitriol that worsens the calcification induced
by phosphate.
To better understand the molecular mechanisms supporting
the opposed effects of calcitriol and paricalcitol on calcifica-
tion, we examined the expression of the BMP2 signaling genes
that appeared to be upregulated in the VSMCs exposed to high
phosphate. Whereas calcitriol increased BMP2 mRNA level,
paricalcitol decreased it. Consistent with this was the upregu-
lation of Runx2 and Msx2 in cells treated with calcitriol and
the downregulation of Runx2 and Msx2 in cells exposed to
paricalcitol. The expression of OC was also increased by
calcitriol, but no change was observed in cells exposed to
paricalcitol. In addition, calcitriol did not change the upregu-
lation of cyclin D1 induced by the high phosphate medium
whereas paricalcitol tended to reduce it. Collectively, these
results indicate that calcitriol and paricalcitol induced a differ-
ent phenotype profile driving human aortic VSMCs toward the
stimulation and the inhibition of the calcification process re-
spectively. This is in line with previous results showing an
increased expression of Runx2 in the aorta of calcitriol-treated
animals (22), while both Runx2 expression and OC expression
were upregulated in the aorta by calcitriol and doxercalciferol
but not by paricalcitol (33).
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Following ligand activation, the VDR binds directly to
specific sequences located near promoters and recruits a variety
of coregulatory complexes that perform the additional func-
tions required to modify transcriptional output (39). Thus
different cell events after activation of the same VDR may
explain why some vitamin D analogs may not promote VC. It
has been demonstrated that the activation of the VDR by
paricalcitol or 22-oxacalcitriol recruits coactivators that are
different from those recruited by calcitriol (18). Additionally,
the differential effect on the calcification process that we have
observed could be explained by a differential modulation of
intracellular signaling pathways. As indicated above, we have
demonstrated in human aortic VSMCs the involvement of
Wnt/-catenin activation in the calcification induced by high
phosphate. Thus we then explored the effect of calcitriol and
paricalcitol on the Wnt/-catenin pathway. The increase in
calcification induced by calcitriol was accompanied with a
concomitant activation of the Wnt/-catenin with the nuclear
translocation of -catenin. This is in agreement with previous
data showing that Wnt signaling proteins are implicated in
bovine artery smooth muscle cell calcification in the presence
of phosphate and vitamin D sterols (49). In addition, we further
verified the implication of Wnt/-catenin activation on cal-
citriol-induced calcification by demonstrating a reduction on
calcification after inhibition of Wnt/-catenin by coincubation
with the specific Wnt antagonist DKK-1. The effect of pari-
calcitol on the Wnt/-catenin pathway was the opposed from
that seen with calcitriol. The inhibition of calcification by
paricalcitol was accompanied by a reduction in nuclear
-catenin expression to levels even lower than those observed
with high phosphate in the medium. Thus our data clearly
demonstrate a differential effect of calcitriol and paricalcitol on
the Wnt/-catenin signaling pathway.
Of note, it has been reported that the VDR can interact with
-catenin via a noncanonical signaling to control different cell
responses (38, 24). Of interest, Pálmer et al. (37) showed that
a number of genes induced by -catenin are regulated through
VDR elements. Thus combined activation of VDR and Wnt
signaling promoted formation of TCF/Lef--catenin and VDR/
-catenin complexes that together induced genes involved in
hair follicle differentiation in adult epidermis; furthermore, the
vitamin D analog EB1089 synergized with -catenin to stim-
ulate hair differentiation. A functional interaction between the
Wnt and 1,25(OH)2D3 pathways has also been proposed in
osteoblasts. Interestingly, VDR activation by 1,25-(OH)2D3
caused upregulation of low-density lipoprotein receptor-related
protein 5, a Wnt coreceptor that plays an important role in bone
formation (10, 21), through its binding to a VDR element (10).
It is tentative to hypothesize that VDR/-catenin interactions
have a role in the development of VC and therefore it may be
affected by calcitriol or paricalcitol. The regulatory role of Wnt
signaling in VCs emerges the possibility of their therapeutic
intervention by targeting this pathway. Indeed, Wnt inhibitors
have shown early promise; however, given the central role of
the Wnt pathway in regulating growth and development in
many tissues, considerable work will be needed to ensure the
safety of these new therapies (60).
In summary, our results suggest differential effects of cal-
citriol and paricalcitol on VC that appears to be mediated by a
distinct regulation of the BMP and Wnt/-catenin signaling
pathways. Calcitriol increased the calcification, which ap-
peared to be associated with the upregulation of the expression
of osteoblastic gene markers as BMP2, Runx2, Msx2, and OC
and the activation of the Wnt/-catenin signaling pathway. By
contrast, paricalcitol decreased calcification, which was ac-
companied by a downregulation of the expression of these
osteoblastic gene markers and the Wnt/-catenin signaling.
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